Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Ciba Corning

This article was originally published in The Gray Sheet

Executive Summary

Ciba Corning: Introduces the ACS PSA2 test for prostate specific antigen. The test, used in the management of prostate cancer patients, is the second PSA assay for use on the firm's ACS:180 testing system. Capable of providing initial results in 15 minutes and offering a throughput of up to 180 tests per hour, the ACS PSA2 also features "a direct measurement range up to 135 ng/mL with automated dilution expanding the routine measurable range to 2,700 ng/mL." Ciba Corning introduced its initial ACS test for PSA in September 1994 following premarket approval for use of the test in prostate cancer management ("The Gray Sheet" Sept. 26, 1994, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005329

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel